Design Therapeutics, Inc. (DSGN) shares fell 25.72 percent to $10.68, down $3.69 on Monday, despite the company reporting positive biomarker and clinical data from its ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 for Friedreich ataxia.
The stock is currently trading at $10.68, compared with a previous close of $14.37 on the Nasdaq. It opened at $15.94 and traded between $10.45 and $16.95 during the session, with volume reaching 3.81 million shares, well above the average daily volume of 397,863 shares.
The company said DT-216P2 increased frataxin expression and produced dose-dependent clinical improvements. In the highest dose cohort, patients showed an average 6.4-point improvement in the modified Friedreich's Ataxia Rating Scale after four weeks of treatment, along with gains in stability and fatigue scores.
Design Therapeutics shares have traded between $3.31 and $17.25 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.